NEK2 and pancreatic neoplasm: In a study of cytological experiments in pancreatic cancer, Zhang et al (111), confirmed that dephosphorylation of PD-L1 by NEK2 is one of the main reasons for the poor immunotherapeutic effect observed with pancreatic cancer.